Abaloparatide: Molecular Structure

Molecular Structure and Properties#

Abaloparatide is a 34-amino-acid synthetic peptide analog of human parathyroid hormone-related protein (PTHrP). It has a molecular weight of approximately 3,960.59 Da, molecular formula C174H300N56O49, and CAS number 247062-33-5. The peptide was designed through systematic modification of the PTHrP(1-34) sequence to optimize selectivity for the RG conformation of the PTH1 receptor while preserving osteoanabolic potency.

Amino Acid Sequence#

The primary structure of abaloparatide is based on the native human PTHrP(1-34) sequence with eight amino acid substitutions concentrated in the C-terminal half of the molecule:

[Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2

The first 20 amino acids are identical to native PTHrP(1-34), preserving the N-terminal domain critical for PTH1R activation. The C-terminal modifications (positions 22-34) alter receptor binding kinetics without compromising receptor potency.

Key structural features:

• Positions 1-20: Identical to native PTHrP(1-34); this region contains the receptor activation domain
• Position 22 (Glutamic acid): Replaces native residue to modify receptor dissociation kinetics
• Position 23 (Leucine): Enhances alpha-helical stability in the C-terminal domain
• Position 25 (Glutamic acid): Contributes to electrostatic interactions favoring RG binding
• Position 26, 30 (Lysine): Positively charged residues for receptor surface contact
• Position 29 (Alpha-aminoisobutyric acid, Aib): Non-natural amino acid that constrains backbone conformation and enhances proteolytic resistance
• C-terminal amidation: The C-terminus is amidated (NH2), which enhances peptide stability and receptor binding

RG-Selective Receptor Binding#

The defining pharmacological feature of abaloparatide is its preferential binding to the RG (G protein-coupled) conformation of PTH1R rather than the R0 (ligand-independent) conformation. This selectivity has important functional consequences:

1. Transient cAMP signaling: RG binding produces a brief, rapidly reversible cAMP signal that activates protein kinase A (PKA) and downstream osteoblast differentiation pathways. The transient signal favors anabolic bone formation.

2. Reduced R0 engagement: The R0 conformation mediates prolonged, sustained cAMP signaling that activates both osteoblast and osteoclast pathways, stimulates calcium mobilization, and contributes to bone resorption. Abaloparatide's reduced R0 binding limits these effects.

3. Clinical implications: RG selectivity is hypothesized to explain why abaloparatide produces similar bone formation stimulation to teriparatide but with less bone resorption stimulation, lower hypercalcemia rates, and potentially greater net cortical bone gains (particularly at the hip).

This receptor binding model distinguishes abaloparatide from both teriparatide (PTH(1-34), which binds both RG and R0 more equally) and native PTH(1-84) (which has even greater R0 engagement).

Physicochemical Properties#

Abaloparatide is formulated as a clear, colorless solution for subcutaneous injection.

Formulation: The Tymlos pen contains abaloparatide in a solution with phenol (preservative), water for injection, and adjusted to physiological pH. Each pre-filled pen delivers 80 mcg per dose.

• Solubility: Soluble in aqueous buffers at physiological pH
• Stability: Stable under refrigerated conditions (2-8 degrees C) prior to first use; stable at room temperature (20-25 degrees C) for up to 30 days after first use
• Appearance: Clear, colorless solution; do not use if cloudy, discolored, or containing particles

Pharmacokinetics#

Abaloparatide exhibits rapid absorption and short systemic exposure following subcutaneous injection, consistent with its intended use as a pulse-mode osteoanabolic agent.

Absorption: After subcutaneous injection of 80 mcg, abaloparatide is rapidly absorbed with a median time to maximum concentration (Tmax) of approximately 0.51 hours (approximately 30 minutes). The absolute bioavailability is approximately 36%.

Distribution: The mean apparent volume of distribution is approximately 50 liters following subcutaneous administration.

Metabolism: Abaloparatide is expected to be degraded into small peptide fragments by non-specific proteolytic enzymes, consistent with other peptide therapeutics. It does not undergo CYP-mediated metabolism.

Elimination: The terminal half-life is approximately 1 hour following subcutaneous administration. The short half-life ensures transient PTH1R activation with each daily dose, maintaining the anabolic window critical for net bone formation.

Structural Comparison with Related Peptides#

The osteoanabolic peptide class includes agents that activate PTH1R through different binding profiles:

• vs. Teriparatide (PTH(1-34)): Teriparatide is the first 34 amino acids of native PTH, while abaloparatide is based on the PTHrP sequence with C-terminal modifications. Teriparatide has greater R0 binding, producing longer-lasting cAMP signals that drive both bone formation and resorption. Teriparatide has a longer half-life (~1 hour) and higher hypercalcemia rates (6.4% vs 3.4%).
• vs. Native PTHrP(1-34): Abaloparatide retains the N-terminal 20 residues of PTHrP but has 8 substitutions in positions 22-34 that enhance RG selectivity and metabolic stability beyond the native sequence.
• vs. Native PTH(1-84): Full-length PTH has substantial R0 binding and promotes both bone formation and resorption. It was previously marketed as Natpara for hypoparathyroidism but withdrawn due to device issues.

Related Reading#

• Abaloparatide overview and research guide
• Peptides similar to Abaloparatide
• Abaloparatide research evidence